1. Second generation direct-acting antivirals – Do we expect major improvements? 
Jordan J. Feld, Graham R. Foster 
Journal of Hepatology 
Volume 65, Issue 1, Pages S130-S142 (October 2016)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
The challenge of G3 cirrhosis. SVR rates are shown with currently and soon-to-be approved regimens for patients with genotype 3 and cirrhosis. Although encouraging progress has been made, results for this sub-group of patients remain suboptimal compared to other populations.
Journal of Hepatology  , S130-S142DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Schematic representation of DAA development in order to reach global HCV elimination. The vast majority of patients who receive all oral DAA therapy will achieve sustained virological response (green). However, a second generation of drugs will address the unresolved issues for patients where current treatments are still not satisfactory (red; blue bubbles). Refinement of drug delivery approaches will be necessary to achieve ‘cure-all’ treatments.
Journal of Hepatology  , S130-S142DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions